Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Chemotherapy
FGFR3
Platinum
Urothelial cancer
Journal
European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
03
03
2020
accepted:
16
07
2020
pubmed:
6
8
2020
medline:
23
7
2021
entrez:
6
8
2020
Statut:
ppublish
Résumé
Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in ∼15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas (mUCs). To determine the association between FGFR3 status and response to platinum-based chemotherapy in patients with MIBC or mUC. The authors conducted a retrospective review and comparison of patients having (1) MIBC treated with neoadjuvant chemotherapy (NAC), (2) mUC treated with first-line platinum-based chemotherapy (M1 cohort), and (3) MIBC who were from The Cancer Genome Atlas (TCGA). Platinum-based chemotherapy. Pathologic response, recurrence-free (RFS) or progression-free (PFS) survival, and overall survival (OS) were compared between patients with FGFR3 alteration (FGFR3alt) and those without it (FGFR3wild type [FGFR3wt]) in the three cohorts. Nine of 72 NAC patients (13%) had FGFR3alt, of whom none had pathologic complete response and three had residual non-MIBC (carcinoma in situ, n = 1; pT1, n = 2). FGFR3alt was associated with shorter RFS (hazard ratio, 2.74; p = 0.044) but not OS. Among TCGA patients who underwent adjuvant chemotherapy (n = 74), FGFR3alt patients had shorter RFS as well. Conversely, among chemotherapy-naive TCGA patients, FGFR3alt was associated with longer RFS and OS. In the M1 cohort (FGFR3alt, n = 27; FGFR3wt, n = 81), FGFR3alt was associated with higher rates of pulmonary metastases and nonregional lymphadenopathy. Despite lower response rates among FGFR3alt patients (37% vs 49%; p = 0.056), PFS and OS were not significantly different from FGFR3wt patients. FGFR3 status is associated with lower responses to platinum-based chemotherapy, which may prompt exploration of nonchemotherapeutic approaches for perioperative management of FGFR3alt urothelial cancers. Approximately 15% of bladder cancers harbor mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. Our findings suggest that FGFR3 mutations might be associated with lower responses and shorter time to recurrence among patients with muscle-invasive bladder cancer who received perioperative platinum-based chemotherapy. FGFR3 status does not significantly impact response to chemotherapy among those with metastatic urothelial cancers.
Sections du résumé
BACKGROUND
Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in ∼15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas (mUCs).
OBJECTIVE
To determine the association between FGFR3 status and response to platinum-based chemotherapy in patients with MIBC or mUC.
DESIGN, SETTING, AND PARTICIPANTS
The authors conducted a retrospective review and comparison of patients having (1) MIBC treated with neoadjuvant chemotherapy (NAC), (2) mUC treated with first-line platinum-based chemotherapy (M1 cohort), and (3) MIBC who were from The Cancer Genome Atlas (TCGA).
INTERVENTION
Platinum-based chemotherapy.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
Pathologic response, recurrence-free (RFS) or progression-free (PFS) survival, and overall survival (OS) were compared between patients with FGFR3 alteration (FGFR3alt) and those without it (FGFR3wild type [FGFR3wt]) in the three cohorts.
RESULTS AND LIMITATIONS
Nine of 72 NAC patients (13%) had FGFR3alt, of whom none had pathologic complete response and three had residual non-MIBC (carcinoma in situ, n = 1; pT1, n = 2). FGFR3alt was associated with shorter RFS (hazard ratio, 2.74; p = 0.044) but not OS. Among TCGA patients who underwent adjuvant chemotherapy (n = 74), FGFR3alt patients had shorter RFS as well. Conversely, among chemotherapy-naive TCGA patients, FGFR3alt was associated with longer RFS and OS. In the M1 cohort (FGFR3alt, n = 27; FGFR3wt, n = 81), FGFR3alt was associated with higher rates of pulmonary metastases and nonregional lymphadenopathy. Despite lower response rates among FGFR3alt patients (37% vs 49%; p = 0.056), PFS and OS were not significantly different from FGFR3wt patients.
CONCLUSIONS
FGFR3 status is associated with lower responses to platinum-based chemotherapy, which may prompt exploration of nonchemotherapeutic approaches for perioperative management of FGFR3alt urothelial cancers.
PATIENT SUMMARY
Approximately 15% of bladder cancers harbor mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. Our findings suggest that FGFR3 mutations might be associated with lower responses and shorter time to recurrence among patients with muscle-invasive bladder cancer who received perioperative platinum-based chemotherapy. FGFR3 status does not significantly impact response to chemotherapy among those with metastatic urothelial cancers.
Identifiants
pubmed: 32753285
pii: S0302-2838(20)30566-2
doi: 10.1016/j.eururo.2020.07.018
pmc: PMC8215618
mid: NIHMS1618823
pii:
doi:
Substances chimiques
Platinum
49DFR088MY
FGFR3 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 3
EC 2.7.10.1
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
907-915Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA221745
Pays : United States
Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Références
Urology. 2005 Dec;66(6 Suppl 1):4-34
pubmed: 16399414
Eur Urol. 2019 Nov;76(5):599-603
pubmed: 31272788
Exp Ther Med. 2019 Aug;18(2):1226-1234
pubmed: 31316618
Clin Cancer Res. 2019 Feb 1;25(3):967-976
pubmed: 30352907
J Clin Oncol. 2018 Jul 1;36(19):1949-1956
pubmed: 29742009
Clin Cancer Res. 2017 Jul 15;23(14):3610-3618
pubmed: 28137924
Cancer. 2018 Jul 1;124(13):2785-2800
pubmed: 29786848
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
J Clin Oncol. 2005 Jul 20;23(21):4602-8
pubmed: 16034041
Nat Commun. 2019 Jul 5;10(1):2977
pubmed: 31278255
Eur Urol. 2015 Dec;68(6):959-67
pubmed: 26238431
Clin Cancer Res. 2019 Apr 15;25(8):2458-2470
pubmed: 30593515
Nat Rev Cancer. 2010 Feb;10(2):116-29
pubmed: 20094046
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
N Engl J Med. 2019 Jul 25;381(4):338-348
pubmed: 31340094
Urol Oncol. 2014 Jan;32(1):49.e23-31
pubmed: 24360661
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Eur Urol. 2017 Dec;72(6):952-959
pubmed: 28583311
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821